IRIS - Res&Arch Institutional Research Information System - Research & Archive

BELLINI, RACHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 162
EU - Europa 111
AS - Asia 105
AF - Africa 1
Totale 379
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 161
HK - Hong Kong 56
IE - Irlanda 47
IT - Italia 47
SG - Singapore 36
CN - Cina 7
FI - Finlandia 5
KR - Corea 5
BE - Belgio 3
AT - Austria 2
DE - Germania 2
CA - Canada 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
EE - Estonia 1
IR - Iran 1
NL - Olanda 1
SE - Svezia 1
Totale 379
Salva come PNG Salva come JPEG
Città #
Hong Kong 56
Dublin 43
Chandler 40
Boardman 25
Singapore 25
Perugia 20
Los Angeles 5
Seoul 5
Florence 4
Lappeenranta 4
Medford 4
Princeton 4
San Mateo 4
Brussels 3
Dallas 3
Wilmington 3
Altamura 2
Bologna 2
Houston 2
Lawrence 2
Menlo Park 2
Naples 2
San Diego 2
Vienna 2
Abidjan 1
Ann Arbor 1
Ashburn 1
Boydton 1
Brno 1
Cambridge 1
Den Haag 1
Frankfurt am Main 1
Fremont 1
Helsinki 1
Jacksonville 1
Lugano 1
Philadelphia 1
Redmond 1
Seattle 1
Tallinn 1
Tenhult 1
Toronto 1
Zanjan 1
Totale 283
Salva come PNG Salva come JPEG
Nome #
Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction 43
GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation 37
Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling 36
Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease 35
Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis 33
Combinatorial therapy with BAR502 and UDCA resets FXR and GPBAR1 signaling and reverses liver histopathology in a model of NASH 32
Repositioning Mifepristone as a Leukaemia Inhibitory Factor Receptor Antagonist for the Treatment of Pancreatic Adenocarcinoma 31
Discovery of BAR502, as potent steroidal antagonist of leukemia inhibitory factor receptor for the treatment of pancreatic adenocarcinoma 27
Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury 24
Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling 23
Discovery of a Novel Class of Dual GPBAR1 Agonists-RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders 18
Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease 18
The leukemia inhibitory factor regulates fibroblast growth factor receptor 4 transcription in gastric cancer 11
Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis 11
Activation of GPBAR1 attenuates vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease 10
Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases 6
Totale 395
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.493
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.493
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 4 1 0
2021/202231 0 2 0 0 0 0 9 4 0 10 1 5
2022/2023170 9 13 0 9 21 17 0 7 82 0 6 6
2023/2024128 6 8 3 5 11 1 28 12 19 6 19 10
2024/202561 6 29 25 1 0 0 0 0 0 0 0 0
Totale 395